Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Taxes (2017 - 2019)

Historic Current Taxes for CytomX Therapeutics (CTMX) over the last 3 years, with Q1 2019 value amounting to $13.4 million.

  • CytomX Therapeutics' Current Taxes rose 119217.39% to $13.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $13.4 million, marking a year-over-year increase of 119217.39%. This contributed to the annual value of $13.3 million for FY2018, which is 133380000.0% up from last year.
  • As of Q1 2019, CytomX Therapeutics' Current Taxes stood at $13.4 million, which was up 119217.39% from $13.3 million recorded in Q4 2018.
  • In the past 5 years, CytomX Therapeutics' Current Taxes ranged from a high of $13.4 million in Q1 2019 and a low of $1000.0 during Q4 2017
  • In the last 3 years, CytomX Therapeutics' Current Taxes had a median value of $3.8 million in 2018 and averaged $5.9 million.
  • Its Current Taxes has fluctuated over the past 5 years, first soared by 133380000.0% in 2018, then surged by 119217.39% in 2019.
  • Over the past 3 years, CytomX Therapeutics' Current Taxes (Quarter) stood at $1000.0 in 2017, then soared by 1333800.0% to $13.3 million in 2018, then grew by 0.26% to $13.4 million in 2019.
  • Its Current Taxes stands at $13.4 million for Q1 2019, versus $13.3 million for Q4 2018 and $5.0 million for Q3 2018.